Seres Therapeutics (NASDAQ:MCRB) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Seres Therapeutics (NASDAQ:MCRB) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.03, Fidelity Earnings reports. The firm had revenue of $7.03 million during the quarter, compared to analyst estimates of $6.69 million.

Shares of Seres Therapeutics stock traded down $0.34 on Thursday, reaching $3.72. 260,000 shares of the company’s stock were exchanged, compared to its average volume of 194,233. The company has a market capitalization of $265.67 million, a P/E ratio of -1.53 and a beta of 1.78. Seres Therapeutics has a 52 week low of $2.02 and a 52 week high of $9.00. The firm’s 50-day moving average is $3.53 and its two-hundred day moving average is $3.64.

MCRB has been the subject of several recent research reports. Zacks Investment Research downgraded Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. Chardan Capital reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Thursday, September 19th. BidaskClub downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Cowen reissued a “buy” rating on shares of Seres Therapeutics in a research report on Monday. Finally, ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $10.33.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

See Also: How to Use a Moving Average for Trading 

Earnings History for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.